Facebook
X
LinkedIn
ForwardThe Underlying Neurologic Mechanisms of RCC (Module 2)
Program / Course Description
Refractory Chronic Cough (RCC) affects millions and often persists despite optimal treatment, posing a significant clinical challenge. Increasing evidence points to complex neurological mechanisms—such as heightened sensory nerve activity and cough hypersensitivity—as key contributors to RCC.
This multimodal activity breaks down the evolving science of RCC into brief, targeted microlearning segments. Clinicians learn about neural pathways, receptor targets, and emerging therapies through expert commentary, interactive gaming, and an animated video.
Target Audience
The target audience for this educational initiative will be U.S. based health care professionals who care for patients with RCC, including pulmonologists, primary care providers (family physicians, internists, physician associates, nurse practitioners, and other nursing professionals), and specialists such as allergists, gastroenterologists, ENTs (ear, nose, and throat specialists), and speech pathologists.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Identify the underlying neurologic mechanisms that contribute to cough hypersensitivity and their basis as treatment targets for RCC
Commercial Support Acknowledgment
This activity is supported by an independent medical educational grant from GSK.
Copyright Information
Copyright © 2025 American Thoracic Society. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without written permission from American Thoracic Society.
Faculty
Peter Dicpinigaitis, MD
Professor of Medicine at the Albert Einstein College of Medicine
Division of Critical Care Medicine at Montefiore Medical Center
Montefiore Cough Center
Bronx, NY
Disclosures
GlaxoSmithKline, Hyfe, Merck, Nocion, Trevi | Consultant
Matthew Drake, MD, ATSF
Division Head, Division of Pulmonary, Allergy and Critical Care
Edwards Professor of Pulmonary Medicine
Principal Investigator, OHSU Asthma Lab
Oregon Health & Science University
Portland, OR
Disclosures
AstraZeneca, GlaxoSmithKline, Merck, Sanofi, Trevi | Consultant
Planning Committee
Peter Dicpinigaitis, MD
Professor of Medicine at the Albert Einstein College of Medicine
Division of Critical Care Medicine at Montefiore Medical Center
Montefiore Cough Center
Bronx, NY
Disclosures
GlaxoSmithKline, Hyfe, Merck, Nocion, Trevi | Consultant
Michael Blaiss, MD
Clinical Professor
Medical College of Georgia at Augusta University
Augusta, GA
Disclosures
ALK-Abello, Inc, AstraZeneca, Bryn, GlaxoSmithKline, Prollergy, Regeneron Pharmaceuticals, Sanofi | Consultant
Matthew Drake, MD, ATSF
Division Head, Division of Pulmonary, Allergy and Critical Care
Edwards Professor of Pulmonary Medicine
Principal Investigator, OHSU Asthma Lab
Oregon Health & Science University
Portland, OR
Disclosures
AstraZeneca, GlaxoSmithKline, Merck, Sanofi, Trevi | Consultant
Anju T. Peters, MD, MSCI
Professor of Medicine
Associate Chief of Clinical Research and Practice Innovation
Division of Allergy and Immunology
Director, Center for Clinical Research
Northwestern University Clinical and Translational
Sciences Institute (NUCATS)
Medical Director, Northwestern Medicine Clinical Research Unit
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
AstraZeneca, Chiesi Farmaceutici, Eli Lilly and Company, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Sanofi, Genzyme | Consultant
Rachel M. Taliercio, DO
Vice Chair - Safety Quality and Patient Experience
Respiratory Medicine
Integrated Hospital-Care Institute
Assistant Professor | CCLCM of CWRU
Cleveland, OH
Disclosures
GlaxoSmithKline | Consultant
Charles Vega, MD, FAAFP
Clinical Professor, Family Medicine
Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine
Associate Dean UC-Irvine College of Medicine
Irvine, CA
Disclosures
Boehringer Ingelheim, Exact Sciences | Consultant
Anna Goddard, PhD
Manager of Medical Content
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Amanda Noe
Senior Manager, Medical Education and Client Services
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Erika Fox
Senior Project Manager
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
Jennifer Siegel-Gasiewski, MPA
Director of Lifelong Learning
American Thoracic Society
New York, NY
Disclosures
Nothing to disclose
Content Reviewer
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures
Nothing to disclose
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships is present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org)
All relevant financial relationships have been reviewed and mitigated.
The section below is currently not in use
ACCREDITED PROVIDERS
Provided by the American Thoracic Society
Accreditation Statement – American Thoracic Society
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation (American Thoracic Society)
The American Thoracic Society designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American academy of Family Physicians
The AAFP has reviewed RCC in FOCUS: Addressing the Unmet Needs of Refractory Chronic Cough and deemed it acceptable for AAFP credit.
Term of approval is from 7/9/2025 to 7/9/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This session, The Underlying Neurologic Mechanisms of RCC, is approved for 0.75 enduring AAFP Elective credits.
Accreditation Statement- The France Foundation
In support of improving patient care, this activity has been planned and implemented by The France Foundation, the American Thoracic Society, and the American Academy of PAs. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Nurses (The France Foundation)
The France Foundation designates this activity for 0.75 contact hours.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until July 7, 2026. PAs should only claim credit commensurate with the extent of their participation.
Pharmacists (The France Foundation)
This knowledge-based activity, UAN JA0007204-0000-25-062-H01-P, qualifies for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]).
All other health care professionals completing this course will be issued a statement of participation.
Available Credit
- 0.75 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this Enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Participation
Take Activity / Course Instructions
If you are requesting AMA credits or a certificate of participation, your certificate will be available for download.
CME Certificates of credit/attendance will be awarded based on the participant attending the activity, completing and submitting an evaluation and attesting to the credits earned. A CME certificate will be available upon successful completion.
All other healthcare professionals completing this course will be issued a certificate of participation.
The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.
Required Hardware/software
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers.
Additionally, this site and its activities are best viewed using the latest Operating System for your device.